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The case-control design is widely used in retrospective database studies, often
leading to spectacular findings. However, results of these studies often cannot
be replicated, and the advantage of this design over others is questionable. To
demonstrate the shortcomings of applications of this design, we replicate two
published case-control studies. The first investigates isotretinoin and ulcera-
tive colitis using a simple case-control design. The second focuses on dipeptidyl
peptidase-4 inhibitors and acute pancreatitis, using a nested case-control design.
We include large sets of negative control exposures (where the true odds ratio
is believed to be 1) in both studies. Both replication studies produce effect size
estimates consistent with the original studies, but also generate estimates for the
negative control exposures showing substantial residual bias. In contrast, apply-
ing a self-controlled design to answer the same questions using the same data
reveals far less bias. Although the case-control design in general is not at fault,
its application in retrospective database studies, where all exposure and covari-
ate data for the entire cohort are available, is unnecessary, as other alternatives
such as cohort and self-controlled designs are available. Moreover, by focusing
on cases and controls it opens the door to inappropriate comparisons between
exposure groups, leading to confounding for which the design has few options
to adjust for. We argue that this design should no longer be used in these types of
data. At the very least, negative control exposures should be used to prove that
the concerns raised here do not apply.
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1 BACKGROUND
Case-control1 studies consider the question “are persons with a specific disease outcome exposed more frequently to a
specific agent than those without the disease?” Thus, the central idea is to compare “cases,” ie, individuals that experience
the outcome of interest with “controls,” ie, individuals that did not experience the outcome of interest. Often, onematches
controls to cases based on characteristics such as age and sex tomake themmore comparable. The comparison focuses on
differential exposure to the agents of interest in the two groups; greater exposure amongst the cases than amongst the con-
trols suggests a possible positive association. Perhaps the greatest success of the case-control design stands its contribution
to the evidence that smoking causes lung cancer.2 Since this landmark finding, researchers increasingly have applied the
design, occasionally generating spectacular findings leading to headlines in major news outlets, such as a recent study
linking anticholinergic drugs to an increased risk of dementia,3 or another recent study linking immunosuppressants to
a lower risk of Parkinson's disease.4
The case-control design was originally developed to support prospective studies in situations where data on subjects
were costly to acquire, and study budgets did not allow for recruiting and following large cohorts.5 However, its appli-
cation in retrospective database studies, for example those using electronic health records and insurance claims where
longitudinal person-level data have already been captured and the analysis is performed solely within the resident data,
has become commonplace. Because the data already exist, and their acquisition is a sunk cost, the efficiency argument
that initially justified the design becomes a moot point. The added value over other designs for these type of retrospective
data is therefore questionable. Along these lines, Schneeweiss provided similar conceptual argument against this design
in 20106; our prior research published in 2013 showed empirical evidence that it is prone to substantial bias when using
retrospective data,7 and others have reported on the lack of reproducibility of such case-control studies in 1988.8 Yet,
despite all these prior concerns, the number of publications applying this design has increased dramatically over time.
Using a specific PubMed query, we identify 1801 publications in the last 5 years that employ the case-control design in a
retrospective database study (see Supplementary Materials).
Here, we aim to describe the mechanisms that lead to bias in clinical case-control studies using retrospective longitudi-
nal data. We reproduce two published studies to demonstrate this problem, showing that both studies are likely severely
biased, and show that an alternative design is equally viable given the same data, and demonstrates considerably less bias.
We not only argue against further use of the case-control designs in situations where other designs such as a comparative
cohort analysis or self-controlled design are equally viable, but we also highlight a set of study diagnostics that researcher
should perform if they insist on using a case-control design anyway.
1.1 Issues with the case-control design
One root cause of trouble is that the case-control design focuses on the definition of cases and their controls, while the
main research question centers on exposed and unexposed. Being “exposed” is often defined as the presence of some
intervention in the patient's record at the time of the outcome, while “unexposed” indicates the absence of such an inter-
vention. However, this begs the question whether exposed and unexposed are comparable. Is someone who has received
a treatment for some serious ailment really comparable to someone else who did not receive that treatment, even when
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matching on age and sex, or nesting in a subpopulationwith a particular disease?While other designs such as the new-user
cohort design makes this comparison explicit, the case-control design obfuscates this essential question of comparability.
A related issue stems from the fact that the case-control design is anchored on the date of the outcome. Any covariates
that we may capture to adjust for differences relative to this date might actually be captured after the exposure of inter-
est was started, thus opening the possibility of erroneously adjusting for causal intermediaries. This problem becomes
uncomfortably clear if we try to rephrase a case-control study as the equivalent cohort study. New-user cohort studies are
anchored on the date the exposure starts, thus allowing baseline covariates to be captured before exposure and ruling out
causal intermediaries. However, often the unexposed group implied by a case-control study has no well-defined index
date when follow-up starts.
One final argument against using a case-control design when the data is already available to also perform a cohort study
is efficiency, ie, by using only a sample of the controls information on other controls is discarded, and a case-control study
estimate will therefore always have lower precision than the estimate of an equivalent cohort study using all data.
Methods
We replicate two recent studies that represent a range of approaches taken in case-control studies. The first study, by
Crockett et al,9 investigates the effect of isotretinoin on the risk of several outcomes including ulcerative colitis (UC) using
a fairly simple design. The second study, by Chou et al,10 investigates dipeptidyl peptidase-4 (DPP-4) inhibitors on the
risk of acute pancreatitis, employing a more complex design with nesting in a cohort of type-2 diabetes mellitus patients,
and additional confounding adjustment through covariates included in amultivariable regression.We replicate these two
studies as faithfully as possible, and additionally include a set of negative control exposures that are not believed to cause
the outcomes of interest such that their true odds ratios (ORs) should be equal to 1. Applying the same design used in the
replication studies to these controls allows us to quantify residual bias in the design.11,12
An overview of our methods is provided next. The full protocol, attached as supplementary information, provides spe-
cific details such as the codes used to identify disease conditions and drug exposures, and the list of negative control
outcomes. The computer code for executing our study is available as open source software at https://github.com/OHDSI/
StudyProtocols/tree/master/EvaluatingCaseControl.
1.2 Data source
For our analyses, we use the IBM® MarketScan® Commercial Claims and Encounters Database (CCAE) that represent
longitudinal data from individuals enrolled inUnited States employer-sponsored insurance health plans. The data include
adjudicated health insurance claims (eg, inpatient, outpatient, and outpatient pharmacy) as well as enrollment data from
large employers and health plans that provide private healthcare coverage to employees, their spouses, and dependents.
Additionally, CCAE captures laboratory tests for a subset of the covered lives. This administrative claims database includes
a variety of fee-for-service, preferred provider organizations, and capitated health plans, captured fromMarch 2000 up to
and including September 2017. The data are transformed to the OMOP Common Data Model version 5.1.
In contrast, the Crockett study used the PharMetrics Patient-Centric Database (IMS Health, Watertown, MA), another
US insurance claims database. The Chou study used the Taiwanese National Health Insurance Research Database.
1.3 Crockett study replication
Both the original study by Crockett et al and our replication define cases as subjects having at least three health-care
contacts with a UC diagnosis code on three different dates, or one UC diagnosis code and exposure to a drug used in UC
treatment. Controls are selected from the overall population, matching on age (with 2-year caliper), gender, and length of
enrollment (90-day caliper). The index date is defined as the date of the outcome for cases, and the date exactly 12months
after enrollment start for controls. The exposure of interest is isotretinoin. Subjects are considered “exposed” if they are
exposed any time in the 12 months prior to the index date. One noteworthy difference with the original study is that our
replication does not match on region or health plan since those data are not available in the CCAE database.
1.3.1 Chou study replication
Both the original study by Chou et al and our replication only consider cases and controls from a patient cohort who had
at least one outpatient or inpatient diagnosis of type-2 diabetes mellitus and who fill at least one prescription of oral anti-
hyperglycemic agents. The cohort entry date is defined as the prescribing date of the first claim of oral antihyperglycemic
agents. To be eligible for the study cohort, patients need to be 18 years old and have claims data for a continuous period
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of at least 12 months before the cohort entry date and 6 months after the cohort entry date. Cases are defined as subjects
having an inpatient diagnosis of acute pancreatitis, with the index date set to the date of diagnosis. Up to four controls
are selected by matching on age (within a 1-year caliper), gender, and time in cohort (within a 1-year caliper), with the
index date set to the index date of the case to which the controls are matched. Subjects are considered exposed if they are
exposed any time in the 30 days prior to the index date.
Additionally, the following risk factors of acute pancreatitis are included in the conditional logistic regression outcome
model, based on occurrence in the year before the index date: gallstone disease, alcohol-related disease, hypertriglyc-
eridemia, cystic fibrosis, neoplasm, obesity, and tobacco use. Both studies also adjust for the Diabetes Complications
Severity Index to account for the potential impacts of the severity of diabetes on the risk of acute pancreatitis, and include
exposure to drugs that might be associated with acute pancreatitis (furosemide, NSAIDs, corticosteroids, antibiotics, and
cancer drugs).
1.3.2 Negative control exposures
We identify a large set of negative control exposures where we are confident they are not causally associated with the
outcome of interest, such that we can assume the true OR is 1. First, we generate a candidate list of negative control
exposures by identifying exposures with no evidence of being causally related to the outcome of interest.13 We search
for this evidence in the literature through MeSH headings14 and natural language processing,15 spontaneous reports of
adverse events,16 and product labels in theUS17 and Europe.18 We then reverse sort the candidate exposures by prevalence
in the longitudinal database and manually curate until at least 35 negative controls remain. For the nested case-control
study (the Chou et al replication), we define a nesting cohort for each negative control exposure by selecting one of the
primary indications of each drug. The negative controls are listed in Appendix 1 of the protocol.
1.3.3 Alternative study design
To demonstrate that alternative designs with better means to adjust for confounding are equally viable in retrospective
database studies, we estimate the same effects using the self-controlled case series (SCCS) design.19 The SCCS compares
the rate of outcomes during exposure to the rate of outcomes during all unexposed time, both before, between, and after
exposures. It is a Poisson regression that is conditioned on the person. Thus, it seeks to answer the following question:
“Given that a patient has the outcome, is the outcome more likely during exposed time compared to nonexposed time?”
Because the SCCS is a self-controlled design, where each person serves as their own control, it is immune to confounding
due to factors that are constant over time.
Crockett et al defined cases and control to be exposed if they were exposed in the 365 days prior to the index date.
Therefore, when approximating that study using the SCCS design, we define subjects to be exposed starting on the day
after treatment initiation and stopping 365 days after the end of their last prescription, allowing for a 30-day gap between
prescriptions. When approximating the Chou study, we define subjects to be exposed starting on the day after treatment
initiation and stopping 30 days after the end of their last prescription, also allowing for a 30-day gap between prescriptions.
For both studies, we exclude the first 365 days of observation to establish exposure status at the start of follow-up, add
a pre-exposure window of 30 days to counter any time-varying effects due to contra-indications, and adjust for age and
season by assuming a constant effect of age and season within each calendar month and using five-knot cubic splines to
model the effect across months.
2 RESULTS
In the Crockett replication, we identify 122 192 cases of UC, which are matched to 366 576 controls (original study: 4428
cases and 21 832 controls). In the Chou replication, we identify 6799 cases of acute pancreatitis, which are matched to
27 196 controls (original study: 1957 cases and 7828 controls).
2.1 Comparability of exposed to unexposed
Table 1 reports the percentage of the 1049 exposed and 487 719 unexposed in our Crockett replication that have an occur-
rence of select diagnosis and medication codes in the year up to a month prior to the exposure start (for exposed) or index
date (for unexposed). We exclude the last month to minimize the risk of detecting precursors of the outcome. Table 1
also reports the standardized difference of means (S.Diff) for each characteristic. Typically, an absolute S.Diff >0.1 is
considered imbalance between the exposure groups. Many characteristics exceed this threshold.
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FIGURE 1 Estimates from the original study (purple triangle), our replication (yellow diamond), and our replication applied to the
negative control exposures (blue dots) for the Crockett replication (left) and the Chou replication (right). Estimates below the dashed line
have p < 0.05. Estimates in the orange area have a calibrated p < 0.05 [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 Estimates from the self-controlled case series (SCCS) design for the exposures of interest (yellow diamond) and the negative
control exposures (blue dots) for the Crockett replication (left) and the Chou replication (right). Estimates below the dashed line have
p < 0.05. Estimates in the orange area have a calibrated p < 0.05 [Colour figure can be viewed at wileyonlinelibrary.com]
Table 2 reports the same statistics for the 4933 exposed and 29 062 unexposed in the Chou replication. One characteristic
exceeds our predefined threshold, and the S.Diff is positive for almost all, suggesting those not exposed toDPP-4 inhibitors
are overall sicker than those that are not exposed.
2.2 Case-control effect size estimates and residual bias
The left panel of Figure 2 evaluates the OR estimate and its standard error for isotretinoin exposure both in the original
study by Crockett et al (OR = 4.36, 95% confidence interval (CI) = 1.97 to 9.66), and our replication study (OR = 3.51,
CI= 3.11 to 3.96) . The figure also includes the negative control exposure estimates, executed under the same study design.
The full list of negative controls and their estimates can be found in the Supplementary Table S1. Note that, even though
for the negative controls the true odds ratio is assumed to be 1, almost all have an estimated OR that would be called
significantly (p < 0.05) greater than 1.
The right panel of Figure 1 evaluates the OR estimate and its standard error for DPP-4 inhibitor exposure both in the
original study by Chou et al (OR = 1.04; CI = 0.89 to 1.21), and our replication study (OR = 1.12, CI = 1.03 to 1.22).
This figure also includes the negative control exposure estimates, executed under the same study design. Many negative
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controls show spurious statistically significant associations. Furthermore, the fact that the orange boundary (which
indicates where the calibrated p-value12 is equal to 0.05), deviates strongly from the dashed line (indicating where the
uncalibrated p-value is equal to 0.05) demonstrates that overall the variability of the estimates of the negative controls is
greater than can be explained by random error alone. While our replication study yields a statistically significant effect
under a nominal p-value, which does not account for systematic error, this finding is unlikely to inform us about the true
effect size, but rather reflects the range of estimates one would expect to observe using this design even when no true
effect exists.
2.3 Self-controlled case series effect size estimates and residual bias
The left panel of Figure 2 shows the incidence rate ratio (IRR) estimates generated using the SCCS for the question
addressed in the Crockett study as well as the negative controls. A much smaller effect (IRR = 1.64; CI = 1.30 to 2.06) is
observed for isotretinoin than in both the original case-control study and our replication, but in the SCCS analysis, this
effect clearly stands out compared to the negative controls, suggesting there might be a true effect. The right panel of
Figure 2 shows the effect estimates for DPP-4 inhibitors (IRR = 1.11; CI = 1.04 to 1.19) are similar to the case-control
studies. Even though the negative controls show less bias than when using the case-control design, this estimate would
still be consistent with the effects observed for the negative controls. The full list of SCCS estimates can be found in the
Supplementary Table S2.
3 DISCUSSION
Our replications of the two published case-control studies produce similar effect size estimates to the original studies,
with highly overlapping CIs, but we also show that these findings are likely caused by bias. This explains why others
studying the same questions have found different answers. For example, Bernstein et al20 reported no association between
isotretinoin and UC (OR = 1.16, CI = 0.56 to 2.20), and Singh et al21 reported a positive association between sitagliptin
(a DPP-4 inhibitor) and acute pancreatitis (OR = 2.01, CI = 1.19 to 3.38). Our use of negative controls clearly shows that
these case-control designs tend to produce biased estimates. We hypothesize that this bias is due to confounding that
stems fromdifferences between the exposure groups and show that exposed and unexposed indeed have different baseline
characteristics.
This brings us to ourmain criticism of applying the case-control designwhen other designs are viable, ie, by focusing on
cases and controls, this design hides the question of comparability between exposed and unexposed. As a consequence,
applications of the case-control design often imply inappropriate comparisons between exposure groups, where especially
the unexposed group is often ill-defined. This, in turn, leads to confounding, and because the design anchors on the
outcome date rather than the exposure date, our hands are tied when we try to adjust for this confounding, because we
must avoid including causal intermediaries.
We have attempted to reframe the Crockett and Chou studies as comparative new-user cohort studies, but found it
impossible to identify appropriate comparator groups with index dates. For example, when should follow-up start for peo-
ple not exposed to isotretinoin in the cohort-study equivalent of the Crockett study? Rather than being a limitation of the
cohort design, we believe these difficulties reveal the inappropriateness of the comparison implied by these case-control
designs.
As an alternative, we reframed the studies as SCCS19 instead. Because of the self-controlled nature of the SCCS design,
it addresses the type of confounding observed for the case-control studies, and may often be suitable for use in these type
of data.22 Consequently, our analysis of the same data using the SCCS designs yields considerably less bias as observed
through the negative control estimates.
A typical response to the biases reported here is that these findings do not apply to any given researcher's specific
case-control study; people agree that the two example studies we show here are problematic, but if we had only modified
the designs in a specific way, all the issues we observe would go away. For example, the use of propensity scores23 or
disease risk scores24 could address between person confounding in case-control studies, but our concern with the use of
these scores is the danger of accidentally including intermediary variables, as well as other issues reported earlier.25 In
general, we find it hard to justify such a blind faith in the ability of minor tweaks to remedy the weaknesses inherent
to the case-control design for these types of data and argue that empirical evidence is needed to support such claims.
Moreover, it is important to remember that the examples we chose reflect what is actually used in published case-control
studies today.
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4 CONCLUSIONS
We cannot stress enough that our criticism does not apply to the case-control design in general. In theory, even a
case-control design applied in a retrospective database study may well be unbiased if all issues raised in this paper are
addressed. However, our main point is that, in such database studies, where all exposure and covariate data are available
for the entire cohort, it is unnecessary to conduct a case-control study, as other alternatives such as the cohort and SCCS
designs are available. Outside of such database studies, a case-control design may be completely justified to reduce the
cost of acquiring the necessary data.
In this paper, we have highlighted several diagnostics that can reveal issues with a case-control study design. If
researchers insist on using the case-control design, we believe the onus lies on them to use these diagnostics to verify that
the concerns raised here do not apply to their study.
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